Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240786 | 0.86 | MEN1 (0.43) | MEN1KMT2AALDH1A1CYP1A2KDM4E | |
| SCHEMBL3201351 | 0.83 | KMT2A (0.55) | MEN1KMT2AALDH1A1CYP1A2KDM4E | |
| SCHEMBL4764432 | 0.78 | CYP1A2 (0.40) | MEN1KMT2AALDH1A1CYP1A2KDM4E | |
| SCHEMBL2059437 | 0.77 | PTGDR2 (0.47) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL26685275 | 0.76 | FBP1 (0.45) | MEN1KMT2AALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL4764421 | 0.75 | CYP1A2 (0.38) | MEN1KMT2AALDH1A1CYP1A2KDM4E | |
| SCHEMBL5412036 | 0.75 | MEN1 (0.49) | MEN1KMT2AALDH1A1KDM4EAKR1B1 | |
| SCHEMBL4288933 | 0.75 | MAPT (0.39) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4288927 | 0.75 | MAPT (0.39) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7387172 | 0.74 | KMT2A (0.39) | MEN1KMT2AALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | MEN1 400/4885KMT2A 2408/4885ALDH1A1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.